Ratings & Reviews

Remicade is an immune-suppressing drug that is used to treat rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Crohn’s disease.  Remicade is manufactured by Centocor Ortho Biotech, Inc. and was first approved by the FDA in 1998.

Side effects associated with Remicade include stomach pain, nausea, heartburn, headache, back pain, rash, chest pain, sudden weight gain, changes in vision, seizures and loss of appetites.   Use of Remicade has also been associated with more serious conditions, such as serious and potentially fatal blood disorders, infections, lymphoma, liver injury, reactivation of hepatitis B, reactivation of tuberculosis, hepatosplenic T-cell lymphoma (“HSTCL”), drug-induced lupus and demyelinating central nervous system disorders.

A study published in the New England Journal of Medicine in 2001 indicated that Remicade may quadruple the risk of developing tuberculosis.  As a result, the FDA has required the inclusion of a black box warning in Remicade labeling.  In August of 2009, the FDA required Remicade manufacturers to update the product’s boxed warning to alert healthcare professionals of an increased risk of lymphoma and other malignancies in children and adolescents who are taking the drug.  In addition, the FDA has continued to receive reports of HSTCL in patients who were taking Remicade.